Share Name Share Symbol Market Type Share ISIN Share Description
Motif Bio Plc LSE:MTFB London Ordinary Share GB00BVVT4H71 ORD 0.01P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 0.50 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
0.40 0.55
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 3.19 -1.51 3
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 0.50 GBX

Motif Bio (MTFB) Latest News

More Motif Bio News
Motif Bio Investors    Motif Bio Takeover Rumours

Motif Bio (MTFB) Discussions and Chat

Motif Bio (MTFB) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Motif Bio trades in real-time

Motif Bio (MTFB) Top Chat Posts

Motif Bio Daily Update: Motif Bio Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MTFB. The last closing price for Motif Bio was 0.50p.
Motif Bio Plc has a 4 week average price of 0p and a 12 week average price of 0p.
The 1 year high share price is 1.75p while the 1 year low share price is currently 0.04p.
There are currently 654,991,023 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Motif Bio Plc is £3,274,955.12.
scottdavid70: 1) charge satisfied at companies house no RNS = no value for shareholders of Motif otherwise a RNS must be issued if it is to have a material impact on the Share Price 2) Patent issued no RNS = no value for shareholders of Motif otherwise a RNS must be issued if it is to have a material impact on the Share Price Pretty simple really - call Walbrook Monday and they will explain. No last minute news before the AGM to save Lumsden. The vote is happening and they have currently achieved zero for shareholders these past 18 months as far as we have been told officially.
scottdavid70: Just looked up the meaning of BONUS and to my surprise it says “crater the company’s share price, fail to do the job you are paid for and hide for over a year, make sure no one can ask you a question and you will be paid a $100,000 BONUS” uncanny!!
computercoders: Well the share price ended evens today. Pretty much sideways all day. I was sitting on the sidelines wondering whether to buy a few. No-one else did today either. Will keep an eye on it tomorrow.
scottdavid70: “Hi this is Motif Bio” Peel Hunt “cha ching” And we get rehires having done nothing before. You can’t make this up Close run thing who has made from this abject failure: Peel Hunt who have done nothing to help the share price since returning or Lumsden
10076968: Scott for me GL's cards were marked when I listened in to an EGM pre phase 3 and I asked him about the share price being pegged back and was there any reason why he didn't raise it with FCA or SEC? Not only did he bat my question away, when I pressed the issue they had the temerity to terminate my call. Not the way to treat a shareholder. Then the amount of times he had the begging bowl out when he should have been deferring his payments.If I'd listened to my gut then it was telling me to get out there and then. I was circa 80-90% up at that time. Greed got the better of me as was confident that mtfb had complied with FDA guidelines in all aspects. Me and a few colleagues who were in here deep went through every scenario of what could happen. None of us had heard of a CRL at that time.Chuffer I had heard about Cloudbuy but never got my fingers burned there thankfully.
lithological heterogeneities: I mentioned weeks ago that I think Medusa19 Life Sciences will RTO into MTFB. Medusa19 just added their own Covid 10 Min ANTIBODY test (from Medusa19 Life Sciences) to go with Avactas 10 min ANTIGEN test from Medusa19 Life Sciences. Medusa19 was set up by the Boohoo millionaire owners to sell Avactas up & coming 10 min test. Now they added a 2nd test Medusa19 are a private company and the Boohoo owners will want to list Medusa19 Life Sciences asap . How on Earth will they get an almost immediate listing to monetise an imminent World Class Covid test ? This was my main hope when i bought in and still is . htTps:// Go to the Companies House website below and click on ea h of the Medusa19 companies (including Medusa19 Life Sciences) and you will the dates of formation which neatly ties in with MTFB since they announced they were looking to RTO a Healthcare related company: htTps:// Things are moving very rapidly at Medusa19. If it's them it will be very soon. If Medusa19 RTO into MTFB it will make alot of investors very wealthy. IF !
scottdavid70: Anyone seen the results for Iclaprim for: 19th August 2019 Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company will be utilising NIAID's suite of preclinical services through JMI Laboratories to evaluate iclaprim against Listeria monocytogenes, a Gram-positive bacteria causing food-borne, life-threatening infections. The study, to be funded by NIAID, follows earlier in vitro testing in which iclaprim was =32-fold more potent than standard-of-care ampicillin and demonstrated consistent extracellular as well as intracellular activity against L. monocytogenes. 24th October 2019 U.S. Army-funded research project to Evaluate Iclaprim Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with the Walter Reed Army Institute of Research (WRAIR) to conduct pre-clinical testing to evaluate novel combinations with iclaprim to improve safety and efficacy administered by a novel enhanced aerosol technology. 22nd May 2019 Motif Bio to Evaluate Orphan Disease Opportunity for Iclaprim in Ophthalmology Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with Otto-von-Guericke University Magdeburg to conduct a study evaluating iclaprim in an in vitro model of ocular toxoplasmosis. The research will focus on toxoplasma chorioretinitis, an orphan disease that is a type of ocular toxoplasmosis, a parasitic disease that may result in severe life-threatening infections and/or blindness. The work will be led by Prof. Dr. Ildiko Rita Dunay, Director, Institute of Inflammation and Neurodegeneration at the university. 1st May 2019 Motif Bio Signs Agreement with Lamellar Biomedical Evaluation of Iclaprim in Combination with LMS-611 for Cystic Fibrosis Lung Infections Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with Lamellar Biomedical Limited (Lamellar) under which Motif Bio will conduct an in vivo pre-clinical study evaluating iclaprim in combination with Lamellar's patented LAMELLASOME™ technology. Iclaprim has been granted U.S. orphan drug designation for Staphylococcus aureus pneumonia in patients with Cystic Fibrosis (CF). Lamellar's LAMELLASOME™ candidate LMS-611, which has mucokinetic (mucus clearing) properties, has demonstrated antibiotic potentiation (the enhancement of certain properties of antibiotics) and has European orphan drug designation for CF. No? If not, Why?
elsol: Zen - to correct you to avoid others getting mislead the charge/guarantee notification from Company's House on Friday (Not HMRC) is the January switch across/loan restructuring (January) of the MTFB PLC topco. guarantee/charge. In exchange Hercules the $7m debt holder took warrants (payment in kind of MTFB share options) in order to register a new charge onto the IP assets themselves that were owned and operated by MTFB Inc. So $7m did not change hands on Friday or just prior and its a bit of smoke and mirrors situation. We are back where we were on Thursday pre-the mistaken interpretation of the situation by some on these BBs (hence spike in share price Friday that is now correcting today). I hope this makes sense.
elsol: Rapidly, you obviously believe there is a very good probability of a near term excess share price return otherwise you would not be wasting so much of your valuable intellectually challenged energy on so many posts on MTFB in recent irrespective of whether the stock price goes up or down a bit in the next week or two is not really important to anyone seriously invested here. The important thing is to have bought into the stock to avoid being locked out at the announcement date of an RTO..and then just wait! Good luck with your strategy if not following the above...I hope you have bought enough shares to enjoy the gross proceeds during the weeks ahead like me and many others on this site.
moneymunch: Fair enough Lionheart, not many shares go up in a straight line but MTFB certainly has had a couple of goes, and so consequently you're always going to get profit takers to bring the share price down, and also a determined effort by the sharebashers, mostly on Lse who have been relentless to deter and discourage. They're either betting short or more likely working to get the price down for the very large buys that we've seen. Lombard's holds 16.85% and the 12.5m buy after close on Friday suggests another TR1 in the pipeline. I'm personally expecting a big bounce next week and if the share bashers are quiet, then we'll know their job is done, a TR1 will drop and the share price will.advance in anticipation of RTO news, which obviously gets closer every day. Gl :-)
Motif Bio share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Motif Bio
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201023 05:54:36